AKT1 and liver cancer: As a negative regulator of PI(3,4,5)P3 level, SHIP2 inhibition in liver cancer cells enhances PI3K/AKT signaling and prevents ROS production after palmitate treatment [29], whereas its overexpression suppresses PI3K/AKT signaling and cell growth in gastric cancer cells [27].